Skip to Main Content
Phase I-II

GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weight

  • Study HIC#:2000027868
  • Last Updated:07/15/2021

If you are between 18 and 55 years of age and are overweight or have obesity you may qualify for a clinical trial evaluating a once weekly medication which may help with weight loss. The SEMA trial is funded by the National Institutes of Health (NIH) and the study medication (semaglutide vs. placebo) is provided at no cost to qualifying participants. Participants with diabetes are not eligible for this study.

  • Age18 years - 55 years
  • GenderBoth
  • Start Date06/25/2020
  • End Date06/30/2025

Eligibility Criteria

Eligibility Criteria


Inclusion Criteria:

  • Age 18-55
  • Weight - Body Mass Index (BMI) >30 and <50 kg/m2
  • No significant medical problems, including no history of diabetes; no history of HgbA1c >6.5%
  • English speaking and able to read English and complete study evaluations
  • Able to travel to New Haven CT for weekly visits (over 3.5 to 4 month study duration)

Exclusion Criteria:

  • Diabetes (diagnosis of diabetes by American Diabetes Association (ADA) criteria
  • Current participation in a weight loss program or weight loss of >10% of total body weight during the prior 6 months
  • History of prior bariatric/weight loss surgery
  • History of pancreatitis, medullary thyroid cancer or MEN syndrome
  • Current, untreated gallbladder disease (gallstones)
  • Current or past alcohol dependence or any substance use disorders, including smoking
  • Current psychiatric medications, anti-obesity medications, or medications which can affect weight
  • Women who are pregnant or lactating or seeking to become pregnant
  • Medical status judged by study physician/APRN as contraindication, including but not limited to any significant current medical conditions, psychiatric or eating disorder



For more information about this study, contact:

Or contact the Help us Discover team on: